Abbott's MDx Sales Fall 8 Percent in Q3 as Total Revenues Decline Slightly | GenomeWeb

NEW YORK (GenomeWeb News) – Abbott today reported that its third-quarter revenues declined a fraction of one percent to $9.77 billion from $9.82 billion as the firm nears its planned split into two separate, publicly-traded companies.

It fell short of Wall Street's consensus estimate for revenues of $9.94 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.